| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Experimental Biology, The Weizmann Institute of Science, Rehovoth, Israel
Urethan leukemogenesis was found to be fairly potent in C57BL mice when the treatment was begun soon after birth (35% incidence) but very weak when the treatment was begun at about 45 days of age (6% incidence). The inhibitory effect of thymectomy on urethan leukemogenesis was not reversed by subsequent implantation of syngeneic newborn thymus, in contrast to such a reversal in the case of radiation leukemogenesis. Possible reasons for the difference are discussed.
1 This investigation was supported by Research Grant CA-05455 of the National Cancer Institute, USPHS.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |